The US FDA has approved Mesoblast's Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months and older. …
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
The Dispatched Podcast 'Week in Review' - 20 February
February 20, 2026 - - Podcast -
PhRMA launches new campaign against the backdrop of a more assertive U.S.
February 19, 2026 - - Latest News -
Why does anyone accept a review outcome that simply affirms a settled order
February 19, 2026 - - Latest News -
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech